Biologics Market Size, Share & Trends Analysis Report By Source (Microbial, Mammalian), By Products (Monoclonal Antibodies, Vaccines, Recombinant Proteins, Antisense, RNAi), By Disease Category, By Manufacturing, And Segment Forecasts, 2020 - 2025
- Report ID: GVR-1-68038-700-1
- Number of Pages: 185
- Format: Electronic (PDF)
- Historical Range: 2014 - 2018
- Industry: Healthcare
Market Segmentation
- Biologics Source Outlook (Revenue, USD Billion, 2014 - 2025)
- Microbial
- Mammalian
- Others
- Biologics Product Outlook (Revenue, USD Billion, 2014 - 2025)
- MABs
- By Application
- Diagnostic
- Biochemical Analysis
- Diagnostic Imaging
- Therapeutic
- Direct MAB Agents
- Targeting MAB Agents
- Protein Purification
- Others
- Diagnostic
- By Type
- Murine
- Chimeric
- Humanized
- Human
- Others
- By Application
- Vaccines
- Recombinant Proteins
- Antisense, RNAi, & Molecular Therapy
- Others
- MABs
- Biologics Disease Category Outlook (Revenue, USD Billion, 2014 - 2025)
- Oncology
- By Product
- MABs
- Vaccines
- Recombinant Proteins
- Antisense, RNAi, & Molecular Therapy
- Others (Certain products under trials related to blood products etc)
- Infectious Diseases
- By Product
- Vaccines
- MABs
- Antisense, RNAi, & Molecular Therapy
- Recombinant Proteins
- Others
- By Product
- Immunological Disorders
- Cardiovascular Disorders
- Hematological Disorders
- Others
- Oncology
- Biologics Manufacturing Outlook (Revenue, USD Billion, 2014 - 2025)
- Outsourced
- In-house
- Biologics Regional Outlook (Revenue, USD Billion, 2014 - 2025)
- North America
- The U.S.
- The U.S. Source Outlook (Revenue, USD Billion, 2014 - 2025)
- Microbial
- Mammalian
- Others
- The U.S. Product Outlook (Revenue, USD Billion, 2014 - 2025)
- MABs
- By Application
- Diagnostic
- Biochemical Analysis
- Diagnostic Imaging
- Therapeutic
- Direct MAB Agents
- Targeting MAB Agents
- Protein Purification
- Others
- Diagnostic
- By Type
- Murine
- Chimeric
- Humanized
- Human
- Others
- By Application
- Vaccines
- Recombinant Proteins
- Antisense, RNAi, & Molecular Therapy
- Others
- MABs
- The U.S. Manufacturing Outlook (Revenue, USD Billion, 2014 - 2025)
- Outsourced
- In-house
- The U.S. Disease Category Outlook (Revenue, USD Billion, 2014 - 2025)
- Oncology
- By Product
- MABs
- Vaccines
- Recombinant Proteins
- Antisense, RNAi, & Molecular Therapy
- Others (Certain products under trials related to blood products etc)
- Infectious Diseases
- By Product
- Vaccines
- MABs
- Antisense, RNAi, & Molecular Therapy
- Recombinant Proteins
- Others
- By Product
- Immunological Disorders
- Cardiovascular Disorders
- Hematological Disorders
- Others
- Oncology
- The U.S. Source Outlook (Revenue, USD Billion, 2014 - 2025)
- Canada
- Canada Source Outlook (Revenue, USD Billion, 2014 - 2025)
- Microbial
- Mammalian
- Others
- Canada Product Outlook (Revenue, USD Billion, 2014 - 2025)
- MABs
- By Application
- Diagnostic
- Biochemical Analysis
- Diagnostic Imaging
- Therapeutic
- Direct MAB Agents
- Targeting MAB Agents
- Protein Purification
- Others
- Diagnostic
- By Type
- Murine
- Chimeric
- Humanized
- Human
- Others
- By Application
- Vaccines
- Recombinant Proteins
- Antisense, RNAi, & Molecular Therapy
- Others
- MABs
- Canada Manufacturing Outlook (Revenue, USD Billion, 2014 - 2025)
- Outsourced
- In-house
- Canada Disease Category Outlook (Revenue, USD Billion, 2014 - 2025)
- Oncology
- By Product
- MABs
- Vaccines
- Recombinant Proteins
- Antisense, RNAi, & Molecular Therapy
- Others (Certain products under trials related to blood products etc)
- Infectious Diseases
- By Product
- Vaccines
- MABs
- Antisense, RNAi, & Molecular Therapy
- Recombinant Proteins
- Others
- By Product
- Immunological Disorders
- Cardiovascular Disorders
- Hematological Disorders
- Others
- Oncology
- Canada Source Outlook (Revenue, USD Billion, 2014 - 2025)
- The U.S.
- Europe
- Germany
- Germany Source Outlook (Revenue, USD Billion, 2014 - 2025)
- Microbial
- Mammalian
- Others
- Germany Product Outlook (Revenue, USD Billion, 2014 - 2025)
- MABs
- By Application
- Diagnostic
- Biochemical Analysis
- Diagnostic Imaging
- Therapeutic
- Direct MAB Agents
- Targeting MAB Agents
- Protein Purification
- Others
- Diagnostic
- By Type
- Murine
- Chimeric
- Humanized
- Human
- Others
- By Application
- Vaccines
- Recombinant Proteins
- Antisense, RNAi, & Molecular Therapy
- Others
- MABs
- Germany Manufacturing Outlook (Revenue, USD Billion, 2014 - 2025)
- Outsourced
- In-house
- Germany Disease Category Outlook (Revenue, USD Billion, 2014 - 2025)
- Oncology
- By Product
- MABs
- Vaccines
- Recombinant Proteins
- Antisense, RNAi, & Molecular Therapy
- Others (Certain products under trials related to blood products etc)
- Infectious Diseases
- By Product
- Vaccines
- MABs
- Antisense, RNAi, & Molecular Therapy
- Recombinant Proteins
- Others
- By Product
- Immunological Disorders
- Cardiovascular Disorders
- Hematological Disorders
- Others
- Oncology
- Germany Source Outlook (Revenue, USD Billion, 2014 - 2025)
- The U.K.
- The U.K. Source Outlook (Revenue, USD Billion, 2014 - 2025)
- Microbial
- Mammalian
- Others
- The U.K. Product Outlook (Revenue, USD Billion, 2014 - 2025)
- MABs
- By Application
- Diagnostic
- Biochemical Analysis
- Diagnostic Imaging
- Therapeutic
- Direct MAB Agents
- Targeting MAB Agents
- Protein Purification
- Others
- Diagnostic
- By Type
- Murine
- Chimeric
- Humanized
- Human
- Others
- By Application
- Vaccines
- Recombinant Proteins
- Antisense, RNAi, & Molecular Therapy
- Others
- MABs
- UK Manufacturing Outlook (Revenue, USD Billion, 2014 - 2025)
- Outsourced
- In-house
- UK Disease Category Outlook (Revenue, USD Billion, 2014 - 2025)
- Oncology
- By Product
- MABs
- Vaccines
- Recombinant Proteins
- Antisense, RNAi, & Molecular Therapy
- Others (Certain products under trials related to blood products etc)
- Infectious Diseases
- By Product
- Vaccines
- MABs
- Antisense, RNAi, & Molecular Therapy
- Recombinant Proteins
- Others
- By Product
- Immunological Disorders
- Cardiovascular Disorders
- Hematological Disorders
- Others
- Oncology
- The U.K. Source Outlook (Revenue, USD Billion, 2014 - 2025)
- Germany
- Asia Pacific
- Japan
- Japan Source Outlook (Revenue, USD Billion, 2014 - 2025)
- Microbial
- Mammalian
- Others
- Japan Product Outlook (Revenue, USD Billion, 2014 - 2025)
- MABs
- By Application
- Diagnostic
- Biochemical Analysis
- Diagnostic Imaging
- Therapeutic
- Direct MAB Agents
- Targeting MAB Agents
- Protein Purification
- Others
- Diagnostic
- By Type
- Murine
- Chimeric
- Humanized
- Human
- Others
- By Application
- Vaccines
- Recombinant Proteins
- Antisense, RNAi, & Molecular Therapy
- Others
- MABs
- Japan Manufacturing Outlook (Revenue, USD Billion, 2014 - 2025)
- Outsourced
- In-house
- Japan Disease Category Outlook (Revenue, USD Billion, 2014 - 2025)
- Oncology
- By Product
- MABs
- Vaccines
- Recombinant Proteins
- Antisense, RNAi, & Molecular Therapy
- Others (Certain products under trials related to blood products etc)
- Infectious Diseases
- By Product
- Vaccines
- MABs
- Antisense, RNAi, & Molecular Therapy
- Recombinant Proteins
- Others
- By Product
- Immunological Disorders
- Cardiovascular Disorders
- Hematological Disorders
- Others
- Oncology
- Japan Source Outlook (Revenue, USD Billion, 2014 - 2025)
- China
- China Source Outlook (Revenue, USD Billion, 2014 - 2025)
- Microbial
- Mammalian
- Others
- China Product Outlook (Revenue, USD Billion, 2014 - 2025)
- MABs
- By Application
- Diagnostic
- Biochemical Analysis
- Diagnostic Imaging
- Therapeutic
- Direct MAB Agents
- Targeting MAB Agents
- Protein Purification
- Others
- Diagnostic
- By Type
- Murine
- Chimeric
- Humanized
- Human
- Others
- By Application
- Vaccines
- Recombinant Proteins
- Antisense, RNAi, & Molecular Therapy
- Others
- MABs
- China Manufacturing Outlook (Revenue, USD Billion, 2014 - 2025)
- Outsourced
- In-house
- China Disease Category Outlook (Revenue, USD Billion, 2014 - 2025)
- Oncology
- By Product
- MABs
- Vaccines
- Recombinant Proteins
- Antisense, RNAi, & Molecular Therapy
- Others (Certain products under trials related to blood products etc)
- Infectious Diseases
- By Product
- Vaccines
- MABs
- Antisense, RNAi, & Molecular Therapy
- Recombinant Proteins
- Others
- By Product
- Immunological Disorders
- Cardiovascular Disorders
- Hematological Disorders
- Others
- Oncology
- China Source Outlook (Revenue, USD Billion, 2014 - 2025)
- Japan
- Latin America
- Brazil
- Brazil Source Outlook (Revenue, USD Billion, 2014 - 2025)
- Microbial
- Mammalian
- Others
- Brazil Product Outlook (Revenue, USD Billion, 2014 - 2025)
- MABs
- By Application
- Diagnostic
- Biochemical Analysis
- Diagnostic Imaging
- Therapeutic
- Direct MAB Agents
- Targeting MAB Agents
- Protein Purification
- Others
- Diagnostic
- By Type
- Murine
- Chimeric
- Humanized
- Human
- Others
- By Application
- Vaccines
- Recombinant Proteins
- Antisense, RNAi, & Molecular Therapy
- Others
- MABs
- Brazil Manufacturing Outlook (Revenue, USD Billion, 2014 - 2025)
- Outsourced
- In-house
- Brazil Disease Category Outlook (Revenue, USD Billion, 2014 - 2025)
- Oncology
- By Product
- MABs
- Vaccines
- Recombinant Proteins
- Antisense, RNAi, & Molecular Therapy
- Others (Certain products under trials related to blood products etc)
- Infectious Diseases
- By Product
- Vaccines
- MABs
- Antisense, RNAi, & Molecular Therapy
- Recombinant Proteins
- Others
- By Product
- Immunological Disorders
- Cardiovascular Disorders
- Hematological Disorders
- Others
- Oncology
- Brazil Source Outlook (Revenue, USD Billion, 2014 - 2025)
- Brazil
- MEA
- South Africa
- South Africa Source Outlook (Revenue, USD Billion, 2014 - 2025)
- Microbial
- Mammalian
- Others
- South Africa Product Outlook (Revenue, USD Billion, 2014 - 2025)
- MABs
- By Application
- Diagnostic
- Biochemical Analysis
- Diagnostic Imaging
- Therapeutic
- Direct MAB Agents
- Targeting MAB Agents
- Protein Purification
- Others
- Diagnostic
- By Type
- Murine
- Chimeric
- Humanized
- Human
- Others
- By Application
- Vaccines
- Recombinant Proteins
- Antisense, RNAi, & Molecular Therapy
- Others
- MABs
- South Africa Manufacturing Outlook (Revenue, USD Billion, 2014 - 2025)
- Outsourced
- In-house
- South Africa Disease Category Outlook (Revenue, USD Billion, 2014 - 2025)
- Oncology
- By Product
- MABs
- Vaccines
- Recombinant Proteins
- Antisense, RNAi, & Molecular Therapy
- Others (Certain products under trials related to blood products etc)
- Infectious Diseases
- By Product
- Vaccines
- MABs
- Antisense, RNAi, & Molecular Therapy
- Recombinant Proteins
- Others
- By Product
- Immunological Disorders
- Cardiovascular Disorders
- Hematological Disorders
- Others
- Oncology
- South Africa Source Outlook (Revenue, USD Billion, 2014 - 2025)
- South Africa
- North America
Report content
Qualitative Analysis
- Industry overview
- Industry trends
- Market drivers and restraints
- Market size
- Growth prospects
- Porter’s analysis
- PESTEL analysis
- Key market opportunities prioritized
- Competitive landscape
- Company overview
- Financial performance
- Product benchmarking
- Latest strategic developments
Quantitative Analysis
- Market size, estimates, and forecast from 2014 to 2025
- Market estimates and forecast for product segments up to 2025
- Regional market size and forecast for product segments up to 2025
- Market estimates and forecast for application segments up to 2025
- Regional market size and forecast for application segments up to 2025
- Company financial performance
GET A FREE SAMPLE
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
Leading SME award by D&B
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
